HealthCare Locator
User Information
OneKey Data
id: 80d4cf12-08b8-43f7-8919-a0cebfed6d15ind_id_onekey: trust_level: 0onekey_id: first_name: first_name_transliterated: last_name: last_name_transliterated: middle_name: middle_name_transliterated: suffix_name: activity_phone: intl_phone: local_phone: intl_fax: title:...
Sign-Up Data
user_id: 80d4cf12-08b8-43f7-8919-a0cebfed6d15userId: 80d4cf12-08b8-43f7-8919-a0cebfed6d15trust_level: 2first_name: ABDALLAHlast_name: NAILIemail: ABDALLAH.NAILI@yopmail.comphone: country: postal_code: city: professional_type: TYP.Pprofessional_type_label: speciality:...
European Commission approves Cabometyx in combination with Opdivo as a first-line treatment for patients living with advanced renal cell carcinoma
Approval based on pivotal Phase III CheckMate -9ER trial data, also recently published in the New England Journal of Medicine1 Trial data showed Cabometyx® (cabozantinib) in combination with Opdivo® (nivolumab)...
ARTICLE 5
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Ut velit mauris, egestas sed, gravida...
